Skip to main content
An official website of the United States government
Email

CEO Perspectives on Launching & Growing Biotech Start-Ups

This NCI SBIR PLAN Webinar Series focuses on: CEO Perspectives on Launching & Growing Biotech Start-Ups

This installment of the PLAN webinar series features discussions with Lu Alleruzzo, CEO of Immunophotonics, and David Anderson, CSO of Immunophotonics, on perspectives on launching and growing biotech startups. Immunophotonics is a clinical-stage biotech company backed by $40M in funding that is developing a novel interventional immuno-oncology product. This discussion covers:

  • Company Launch
  • Maintaining Runway
  • Strategic Vision
  • Milestone Setting
  • Investor Fundraising

 

Watch the recording of the PLAN webinar here.

 

 

Lu Alleruzzo_Immunophotonics

Lu Alleruzzo, M.B.A.

Lu Alleruzzo, M.B.A. is a co-founder and the CEO of Immunophotonics. He received a bachelor’s degree in bioengineering and an MBA with a management emphasis from the University of Missouri–Columbia. He is presently an Entrepreneur in Residence for BioGenerator in addition to serving on the board for a commercial enterprise that generates $15M in annual revenue. Prior to employment at Cerner as well as HP and World Wide Technologies, Mr. Alleruzzo developed a surgical training device and conducted research at the Dalton Cardiovascular Research Center. 

 

 

 

David Anderson - Immunophotonics

David Anderson, Ph.D.

David Anderson, Ph.D. is the Chief Scientific Officer of Immunophotonics. He received his Ph.D. in Immunology and Microbiology at the University of Missouri-Columbia School of Medicine and completed a postdoctoral fellowship in Cellular and Molecular Immunology at the University of Colorado Anschutz Medical Campus. Dr. Anderson has held academic positions at the University of Colorado Health Sciences Center and The Scripps Research Institution. He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory/immunomodulatory and cancer drugs. Dr. Anderson has refereed articles for peer-reviewed journals and has an outstanding record of scientific publications and presentations (35 peer-reviewed publications and over 50 presentations/abstracts), and has received several research awards and 10 patents for his innovative research. He built and managed innovative drug discovery and development companies acquired by Celgene Corporation, Cypress Bioscience, Roche, and Nalo Therapeutics (Samsara BioCapital).

 

 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “CEO Perspectives on Launching & Growing Biotech Start-Ups was originally published by the National Cancer Institute.”

Email